BioAge Stock

bioagelabs.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $321.26MM

BioAge develops a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging by using its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging.

Register To Buy and Sell Shares

For more details on financing and valuation for BioAge, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access BioAge’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BioAge.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

BioAge investors also invested in these private companies

Pivotal bioVenture Partners
Summer VC
AARP Foundation
Springboard Enterprises


Management Team

Kristen Fortney Ph.D
Co-Founder & Chief Executive Officer
Eric Morgen MD
Co-Founder & Chief Operating Officer
BJ Sullivan Ph.D
Chief Strategy Officer
Ann Neale
Chief Development Officer
Peng Leong Ph.D
Chief Business Officer & Therapeutic Area Head, Brain Aging
Paul Rubin MD
Chief Medical Officer & Executive Vice President of Research
Dov Goldstein MD
Chief Financial Officer

Board Members

James Healy Ph.D
Sofinnova Investments
Vijay Pande Ph.D
Andreessen Horowitz

Frequently Asked Questions About BioAge’s Stock

Can you buy BioAge’s stock?
BioAge is not publicly traded on NYSE or NASDAQ in the U.S. To buy BioAge’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell BioAge’s stock?
Yes, you can sell stock of a private company like BioAge. Forge can help you sell your BioAge stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is BioAge’s stock price?
BioAge is a privately held company and therefore does not have a public stock price. However, you may access BioAge’s private market stock price with Forge Data.
What is BioAge’s stock ticker symbol?
BioAge does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

GLP-1 enthusiasm pushes BioAge Labs into new age with $170M series D
Until last year, BioAge Labs' progress could be best described as a slow burn, with a pipeline of longevity-focused medicines taking shape incrementally but consistently. The frenzy around GLP-1s changed all of that, with BioAge’s profile ascending dramatically thanks to being one of a select few biotechs with a combo candidate that might enhance weight loss without muscle loss. Equipped with that potential, and a partnership with Eli Lilly to test the hypothesis, BioAge has closed a $170 million series D led by Sofinnova with contributions from major institutional biotech investors and the venture arms of both the Indianapolis pharma and Amgen.
Eli Lilly partner BioAge raises $170 mln for obesity treatment
BioAge Labs, a biotech startup collaborating with Eli Lilly (LLY.N), opens new tab for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.
Updated on: May 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.